Citigroup’s Abeona Therapeutics ABEO Stock Holding History

Citigroup’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-70,000	Closed	-$297K	–	5661
2024 Q2	$297K	Buy	+70,000	New	+$357K	﹤0.01%	3687
2020 Q1	–	Sell	-192	Closed	-$16K	–	7574
2019 Q4	$16K	Sell	192 -212	-52%	-$15K	﹤0.01%	7013
2019 Q3	$23K	Buy	404 +24	+6%	+$1.8K	﹤0.01%	6640
2019 Q2	$45K	Sell	380 -128	-25%	-$21.5K	﹤0.01%	6566
2019 Q1	$93K	Buy	508 +104	+26%	+$18.6K	﹤0.01%	5809
2018 Q4	$72K	Sell	404 -112	-22%	-$24.4K	﹤0.01%	5926
2018 Q3	$165K	Sell	516 -4	-0.8%	-$1.42K	﹤0.01%	5437
2018 Q2	$208K	Buy	520 +312	+150%	+$136K	﹤0.01%	5025
2018 Q1	$75K	Buy	+208	New	+$77.3K	﹤0.01%	5851

Other funds holding ABEO

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup's ABEO Position: Q1 2026 in Review

Citigroup increased its Abeona Therapeutics (ABEO) stake by 0.26% in Q1 2026, buying an estimated $6.79K and bringing the position to 522,445 shares worth $2.34M. The position accounts for ﹤0.01% of the portfolio, ranked #2572.

Citigroup first reported a position in ABEO in Q2 2015 and has held it in 36 quarters since. The position peaked at $3.9M in Q3 2024. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

Citigroup held 522,445 shares of Abeona Therapeutics worth $2.34M as of Q1 2026.
Citigroup bought 1,358 Abeona Therapeutics shares in Q1 2026, an estimated $6.79K.
Abeona Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #2572 holding.
Citigroup first reported a position in Abeona Therapeutics in Q2 2015 and has held it in 36 quarters since.
Citigroup's Abeona Therapeutics position peaked at $3.9M in Q3 2024.
108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.